Literature DB >> 17531839

Immunopathogenesis of multiple sclerosis.

Smriti M Agrawal1, V Wee Yong.   

Abstract

Multiple sclerosis (MS) is considered an immune-mediated disorder in which immune cells cross the blood-brain barrier to enter the central nervous system (CNS) wherein they augment the neuropathology of the disease. This chapter discusses the role of various immune cell types that contribute to the development and progression of MS. Specifically, the role of T cells, antigen-presenting cells, and components of the innate immune system such as macrophages, B cells, and the complement system are discussed. The involvement of CNS-specific cells such as microglia, astrocytes, and neurons in MS are discussed and the immunosuppressive role of regulatory T cells is considered. We introduce the involvement of chemokines and matrix metalloproteinases which helps recruit immune cells into the CNS in MS. Although the causes of MS are unknown, various factors such as genetic influences, environmental effects, and involvement of infectious agents as potential contributors to MS immune dysfunctions are also considered. With this background, we discuss the mechanisms of the immunomodulators that are used to treat MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531839     DOI: 10.1016/S0074-7742(07)79005-0

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  14 in total

1.  Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis.

Authors:  Khadir Raddassi; Sally C Kent; Junbao Yang; Kasia Bourcier; Elizabeth M Bradshaw; Vicki Seyfert-Margolis; Gerald T Nepom; William W Kwok; David A Hafler
Journal:  J Immunol       Date:  2011-06-08       Impact factor: 5.422

Review 2.  Will the real multiple sclerosis please stand up?

Authors:  Peter K Stys; Gerald W Zamponi; Jan van Minnen; Jeroen J G Geurts
Journal:  Nat Rev Neurosci       Date:  2012-06-20       Impact factor: 34.870

3.  Development of chemical exchange saturation transfer at 7 T.

Authors:  Adrienne N Dula; Elizabeth M Asche; Bennett A Landman; E Brian Welch; Siddharama Pawate; Subramaniam Sriram; John C Gore; Seth A Smith
Journal:  Magn Reson Med       Date:  2011-03-22       Impact factor: 4.668

4.  The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice.

Authors:  Beichu Guo; Elmer Y Chang; Genhong Cheng
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

5.  Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling.

Authors:  Sonemany Salinthone; Vijayshree Yadav; Robynn V Schillace; Dennis N Bourdette; Daniel W Carr
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

6.  Analysis of HLA DR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis.

Authors:  Mojdeh Ghabaee; Asghar Bayati; Shahla Amri Saroukolaei; Mohamad Ali Sahraian; Mohammad Hosein Sanaati; Parisa Karimi; Massoud Houshmand; Homa Sadeghian; Leila Hashemi Chelavi
Journal:  Cell Mol Neurobiol       Date:  2008-08-26       Impact factor: 5.046

7.  Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes.

Authors:  Andrea L O Hebb; Craig S Moore; Virender Bhan; George S Robertson
Journal:  Autoimmune Dis       Date:  2010-12-28

8.  Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation.

Authors:  Lixia Zhang; Shunzong Yuan; Genhong Cheng; Beichu Guo
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

9.  Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.

Authors:  E Croze; K D Yamaguchi; V Knappertz; A T Reder; H Salamon
Journal:  Pharmacogenomics J       Date:  2012-06-19       Impact factor: 3.550

10.  Pathoetiology of multiple sclerosis: are we barking up the wrong tree?

Authors:  Peter K Stys
Journal:  F1000Prime Rep       Date:  2013-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.